JPRN-UMIN000033628招募中未知
Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantation - Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantation
Tokyo Women's Medical University School of Medicine0 个研究点目标入组 15 人开始时间: 2018年8月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with a history of hypersensitivity to components of SGLT2 inhibitors 2. Type 1 diabetes 3. Patients with postoperative ureteral stenosis such as ureteral stent placement 4. Patients with a history of repeated pyelonephritis 5. Patients with severe ketosis or diabetic coma 6. Patients with severe infections, before and after surgery, severe trauma 7. Patients with end-stage renal failure who are undergoing hemodialysis or peritoneal dialysis 8. Pregnant women or patients with potential pregnancy 9. Patients who research managers judged inappropriate as subjects
研究者
相似试验
招募中
不适用
Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients with chronic liver diseaseDiabetic patients with chronic liver diseaseJPRN-UMIN000035015Kitasato University School of Medicine100
已完成
不适用
Efficacy and safety of sodium-glucose cotransporter-2 inhibitor in patients with type 2 diabetesType 2 diabetes mellitusJPRN-UMIN000017625Department of Cardiology, Fukuoka University Hospital.50
已完成
不适用
Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillatioatrial fibrillationJPRN-UMIN000024326Hyogo collage of medicine80
招募中
不适用
Pleiotropic Effects of Sodium glucose co-transporter 2 inhibitor on sympathetic nerve activity and organ network in patients with Type 2 diabetesType2 diabetes patients with multiple atherosclerosis risk factorsType2 diabetesD003924JPRN-jRCTs041200035TAKAMURA Toshinari40
已完成
不适用
Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II DiabetesDiabetes Mellitus, Type 2NCT02317484Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan231